DEFA14A: Anika Therapeutics Defends Director Independence in Response to Glass Lewis Report

Anika Therapeutics issues a statement disagreeing with Glass Lewis's recommendation against the election of director Stephen O. Richard, asserting his independence and urging stockholders to vote in his favor.

Summary

• Anika Therapeutics has released a statement addressing concerns raised by Glass Lewis regarding the independence of director Stephen O. Richard.
• Glass Lewis recommended against Mr. Richard's election at the upcoming Annual Meeting on July 9, 2024.
• Anika's board strongly disagrees, asserting that Mr. Richard meets the company's standards for director independence and has made significant contributions since joining in September 2020.
• Mr. Richard's expertise in financial and risk management, along with his experience at Becton, Dickinson and Company (BD), are cited as valuable assets to the board.
• Anika's annual spending with BD has been declining, from $4.8 million in 2022 to $3.2 million in 2020, representing less than 0.03% of BD's annual revenues of $19.4 billion.
• Anika's standards for director independence state that a material conflict of interest exists only if payments exceed the greater of $1 million or 2% of the other company's consolidated gross revenues, a threshold not met by Anika's spending with BD.
• Mr. Richard's role at BD as Chief Risk Officer and Chief Audit Executive does not involve sales processes or customer accounts, and he has no involvement in Anika's day-to-day operations or supply chain management.
• The agreement between Anika and BD predates Mr. Richard's appointment to the board and was negotiated at arm's length.
• Anika encourages stockholders to vote FOR Mr. Richard at the Annual Meeting.

Sentiment

Score: 7

Explanation: The document conveys a defensive but confident tone, as Anika is actively addressing concerns and defending its director. The sentiment is moderately positive as the company is proactively managing potential governance issues.

Positives

• Anika's board believes Stephen O. Richard is unquestionably independent and encourages stockholders to vote for him.
• Mr. Richard's expertise in financial and risk management is considered a significant asset to the board.
• Anika's spending with BD is below the threshold for a material conflict of interest as defined by the company's standards.
• The agreement between Anika and BD predates Mr. Richard's appointment to the board and was negotiated at arm's length.

Negatives

• Glass Lewis has recommended against the election of Stephen O. Richard as a director.

Risks

• The disagreement with Glass Lewis could influence stockholder votes regarding Mr. Richard's election.
• Continued scrutiny of director independence could lead to further challenges in board composition.

Management Comments

• Anika respectfully disagrees with the GL recommendation against the election of Stephen O. Richard, believes that Mr. Richard is unquestionably independent, and encourages all stockholders to vote FOR Mr. Richard at the Annual Meeting.
• Mr. Richards insights are a significant asset that enhance the Boards diversity of perspectives.
• We continue to welcome the opportunity to engage with the Glass Lewis Research Team and our stockholders to answer any questions related to this years director elections proposal or any other stewardship matters.

Industry Context

This announcement highlights the increasing scrutiny of director independence by proxy advisory firms like Glass Lewis and ISS, and the importance of companies proactively addressing potential conflicts of interest.

Comparison to Industry Standards

• Anika's director independence standards align with NASDAQ corporate governance standards.
• The company's threshold for material conflicts of interest ($1 million or 2% of consolidated gross revenues) is a common benchmark used by many publicly traded companies.
• Other companies in the medical technology sector, such as Stryker or Medtronic, also face similar scrutiny regarding director independence and related-party transactions.

Stakeholder Impact

• The outcome of the director election could impact shareholder confidence and the company's corporate governance profile.
• Employees may be affected by any changes in board leadership or strategic direction.

Next Steps

• Stockholders will vote on the election of directors at the Annual Meeting on July 9, 2024.
• Anika will continue to engage with Glass Lewis and stockholders to address any remaining concerns.

Key Dates

Keywords

Anika Therapeutics, Stephen O. Richard, Glass Lewis, Director Independence, Proxy Statement, Board of Directors, Corporate Governance, Becton Dickinson, Audit Committee, Capital Allocation